The Abstract presented at the CTAD in San Diego now available in the JPAD. EXPEDITION3 A Phase 3 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the… Continue Reading →

Maria Carillon Scientific Executive director of the American Alzheimer Association presented at the the CTAD the perspective from American Alzheimer Association See slides from the key notes CTAD – Carrillo Plenary 2016